Finnish diabetes technology company Mendor has announced an international partnership distribution agreement with a leading pharmaceutical company in the diabetes field, Merck Serono, covering the United Kingdom diabetes market.  Mendor’s first product, a blood glucose meter the Mendor Discreet, is a unique device that contains...

Novo Nordisk and Chip Ganassi Racing Teams announced that the two organizations have entered into a multi-year extension of their partnership sponsoring No. 83 Novo Nordisk Chip Ganassi Racing entry, driven by Charlie Kimball in the IZOD IndyCar Series. Charlie Kimball is the first licensed driver with type 1 diabetes in the history of...

Amylin Pharmaceuticals and Eli Lilly and Company have agreed to terminate their alliance for type 2 diabetes drug, BYETTA (exenatide), and resolve the outstanding litigation between the companies. As part of the agreement, Amylin will take full responsibility for the worldwide development and commercialization of exenatide, starting in...

People with diabetes will help change the lives for others with diabetes in need as they do something in unison – exercise. Every time someone participates in the Big Blue Test and shares the experience on BigBlueTest.org, a donation of life-saving supplies will be made on their behalf to someone with diabetes in need. The Big Blue...

Diamyd Medical announced it has shifted its focus from the development of the diabetes therapy Diamyd® to the the development of drug candidates for the treatment of chronic pain. Earlier this year the company terminated both of its Phase III studieswith the diabetes therapy Diamyd® in Europe and the US because the therapy did not demonstrate...

U.S. District Court for the Southern District of California granted Amylin Pharmaceuticals a temporary restraining order (TRO) related to its litigation with respect to the Amylin / Lilly diabetes collaboration agreement. The TRO restrains Lilly from proceeding with its plans to use the same sales force to sell both exenatide and Boehringer...

Amylin Pharmaceuticals announced that it has filed a lawsuit against Eli Lilly.  Amylin alleges Lilly is engaging in anticompetitive activity and breaching its strategic alliance agreements to maximize commercialization of exenatide currently marketed as BYETTA® (exenatide) injection.  In 2002 the two companies entered an alliance...

Novo Nordisk announced it would appeal the US District Court for the Eastern District of Michigan’s ruling regarding Novo Nordisk’s US patent covering combination drugs Prandin and PrandiMet. The district court ruled that the patent, which covers the combination use of repaglinide and metformin for the treatment of type...

Eli Lilly and Company and Boehringer Ingelheim announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development. Included are Boehringer Ingelheim’s two oral diabetes agents—linagliptin and BI10773—as well as Lilly’s two basal insulin analogues—LY2605541...

The Bristol-Myers Squibb Foundation announced the Together on Diabetes initiative, the largest corporate philanthropic commitment to fighting type 2 diabetes in the United States to date. The $100 million, five year initiative aims to help patients living with type 2 diabetes better manage their disease beyond...